Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia:  The Effects of Atopy on AGA by Rafi, A. W. & Katz, R. M.
International Scholarly Research Network
ISRN Dermatology
Volume 2011, Article ID 241953, 11 pages
doi:10.5402/2011/241953
Clinical Study
Pilot Study of 15 Patients Receiving a New Treatment Regimen for
AndrogenicAlopecia: The Effectsof Atopy on AGA
A.W. Raﬁand R.M.Katz
Hair Cynr-G Inc., 11500 West Olympic Boulevard, No. 630, Los Angeles, CA 90064, USA
Correspondence should be addressed to A. W. Raﬁ, asifraﬁ1@yahoo.com
Received 8 February 2011; Accepted 16 March 2011
Academic Editor: A. R. Ercocen
Copyright © 2011 A. W. Raﬁ and R. M. Katz. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. We examined the eﬃcacy of a new regimen to treat AGA, with attention to male patients who are atopic. Objective.T o
assess the eﬃcacy of a four-part regimen for the treatment of AGA in atopic and nonatopic patients. NuH Hair is a novel topical
combination of ﬁnasteride, dutasteride, and minoxidil, which is blended in a hypoallergenic lotion. The other three components
included Rogaine foam, Propecia, and ketoconazole shampoo. Methods. A prospective pilot study was conducted in 15 patients.
All patients were assessed for the presence of atopy. Each patient served as their own control. All patients were treated speciﬁcally
with NuH Hair and were given the option to add any of the other components of the protocol to their regimen. Photographs were
t a k e no fe a c hp a t i e n t ’ ss c a l pa tm o n t h s0 ,1 ,3 ,6 ,a n d9 .Results. All 15 patients demonstrated signiﬁcant growth of hair. In those
patients who utilized all 4 components, signiﬁcant growth was achieved in as little as 30 days. In those patients who choose only to
utilize NuH Hair, signiﬁcant growth was demonstrated after 3 months. Conclusion. Aggressively treating AGA achieves signiﬁcant
and rapid growth of new hair. This is eﬀective in atopic and nonatopic male patients.
1.Introduction
Male pattern baldness (MPB), also called androgenetic
alopecia (AGA), is the most common form of alopecia found
in men. It aﬀects approximately 30% of men by the age of
30, 50% of men by age 50, and 57% of men by age 60 [1–
4]. MPB is in part genetically determined and is potentially
reversible.WithMPB,oneexperiencesminiaturizationofthe
hair follicles and shortening of the anagen (growth) phase in
the involved hairs. The main androgen responsible for these
changes to the hair follicle is dihydrotestosterone (DHT).
Testosterone is converted to DHT by an enzyme, 5-alpha
reductase (5AR). Men who have a congenital deﬁciency of
5AR (type II) do not experience MPB [5–9].
Most treatment modalities for MPB are not FDA
approved and overall not signiﬁcantly eﬀective. The high
prevalence of MPB, signiﬁcant early age of onset, and large
degree of associated psychosocial morbidity have created a
large market for MPB treatment. Despite the paramount
demand for MPB treatment, there are only two FDA-
approved medications. However, they are costly, require
lifelong treatment, and may have side eﬀects.
The two FDA-approved medications used to treat MPB
include topical minoxidil (Rogaine c; Johnson and John-
son) and ﬁnasteride (Propecia c; Merck). Minoxidil is a
vasodilator which is directly applied to the scalp to stimulate
growth of the hair follicles. Topical minoxidil slows hair
loss for many men, while in some men, it grows new hair.
T h ep r e v i o u sd e g r e eo fh a i rl o s sr e t u r n sw h e ns o l u t i o n
application is discontinued. Minoxidil is available in 2%
and 5% solutions, and a 5% foam version which became
available in 2007. In addition, Propecia 1mg (oral) was
approved by the FDA in 1998 forAGA. Propecia (ﬁnasteride)
is a prescription pill that inhibits the production of the
male hormone dihydrotestosterone (DHT). This is done by
primarilyblocking 5AR(type2),theenzyme,whichconverts
testosterone to DHT. Like minoxidil, it is likely to slow hair
loss but can also stimulate new hair growth. In general, it is
somewhat more eﬀective than minoxidil, and Propecia c is
even more eﬀective when combined with minoxidil. As with
minoxidil, one’s previous degree of hair loss returns when
Propecia c is discontinued.
There are other medications available on the market,
which claim to treat AGA. These medications are, however,2 ISRN Dermatology
Day no. 1-patient (no. 7) group A
(a)
Day no. 90-patient (no. 7) group A
(b)
Figure 1: (a) Note patient no. 7 with stage 7 AGA on Hamilton Norwood Scale. (b) Note substantial growth at frontal scalp with new thick
and more dense hairs.
Day no. 1-patient (no. 7) group A
(a)
Day no. 30-patient (no. 7) group A
(b)
Day no. 60-patient (no. 7) group A
(c)
Day no. 60-patient (no. 7) group A
(d)
Figure 2: (a) Note that the vertex of scalp is nearly void of hair. (b) At day no. 30, though hair is overall shorter, there are new hairs growing
in the vertex. (c) At day no. 60, many new hairs were found at the vertex and the frontal scalp. The overall area on top of the head which was
originally void of hair has decreased in size. (d) Another view of the vertex demonstrates substantial hair growth.
not FDA approved for MPB. Ketoconazole, (Nizoral) sham-
poo,isalsoknowntoinhibit5AR,theenzymewhichconverts
testosterone to DHT. Preliminary research suggests that
ketoconazole shampoo may be beneﬁcial in men suﬀering
from androgenic alopecia [10, 11]. Support for this also
stems from a study in 1998 which compared ketoconazole
shampoo 2% to the proven hair loss drug minoxidil in
men with androgenic alopecia [10]. The study concluded
that hair density, size, and proportion of anagen follicles
were improved almost similarly by both ketoconazole and
2% minoxidil regimens. In addition, since ketoconazole
eﬀectively treats the Pityriasis (also called Malassezia) fungusISRN Dermatology 3
Day no. 1-patient (no. 4) group A
(a)
Day no. 90-patient (no. 4) group A
(b)
Figure 3: (a) Frontal scalp demonstrates overall thin hair distribution.(b) At day no. 90, this patient’s hair density has increased signiﬁcantly
and diﬀusely.
Day no. 1-patient (no. 4) group A
(a)
Day no. 90-patient (no. 4) group A
(b)
Figure 4: (a) Vertex demonstrates minimal thinning of hair overall. (b) At day no. 90, the vertex demonstrates very thick hair growth.
that commonly inhabits the scalp, it was hypothesized that
it may prevent hair loss by reducing inﬂammation from the
fungus, in addition to having antiandrogenic properties. The
researchers were guarded about the meaning of their results.
They suggested that more rigorous studies on larger groups
of men should be done to conﬁrm their ﬁndings and to
evaluate the ideal dosage, formulation, and desirability of
routine treatment. Although no further research in humans
has been undertaken, a study on ketoconazole in 2005
corroborated the existence of a stimulatory eﬀect on hair
growth in mice [12].
In patients who are atopic, there is an increased suscep-
tibility to infection or colonization with various organisms.
For example, Staphylococcal aureus is detected in more than
90% of skin lesions of atopic dermatitis (AD). A superim-
posed dermatophytosis including Trichophyton rubrum and
Malassezia furfur (Pityrosporum ovale) can cause ﬂares of
atopic dermatitis. The rate of isolation of Malassezia from
the skin of AD patients is much higher than from the skin
of healthy control patients without atopy. This fungal (yeast)
organism is also commonly associated with concomitant
seborrheicdermatitisinatopicpatients.Malasseziafurfur isa
lipophilicyeast,andantiyeastIgEantibodieshavebeenfound
in patients with a predominant head and neck eczematous
dermatitis. This common presentation in atopic dermatitis
patients provided the interest in studying our patients with
clinical fungal infection of the head and neck. Thus, it
provides signiﬁcant anecdotal evidence for the correlation of
a superimposed fungal infection of the scalp in patients with
seborrheic dermatitis and MPB [13].
Anecdotal reports indicate that both the 1% and 2%
dosages of ketoconazole shampoo have hair loss beneﬁts;
however, the more potent 2% formulation likely produces
better results. Excessive usage of either formulation has not
been shown to produce better results. The results produced
in this study were based on ketoconazole 2% shampoo, used
once every 2–4days, and leaving the shampoo on the scalp
for 3–5minutes before rinsing (as is recommended with the
treatmentofdandruﬀandseborrheicdermatitis).Ithasbeen
stated that medications capable of maintaining the existing
hair population, even in the absence of hair regrowth,
s h o u l db er e g a r d e da se ﬀective treatments for androgenic
alopecia. Ketoconazole shampoo is only FDA approved for
the treatment of dandruﬀ and seborrheic dermatitis of the
scalp. Therefore, it cannot be endorsed or marketed as a hair
loss remedy to the general public [11].4 ISRN Dermatology
Day no. 1-patient (no. 4) group A
(a)
Day no. 90-patient (no. 4) group A
(b)
Figure 5: (a) Patient no. 4’s hairline has thinning areas. (b) At day no. 90, this patient’s hairline is much more deﬁned and thicker.
Day no. 1-patient (no. 6) group C
(a)
Day no. 90-patient (no. 6) group C
(b)
Day no. 90-patient (no. 6) group C
(c)
Figure 6: (a) Diﬀuse thinning of the frontal scalp and vertex is noted. (b) At day no. 90, thick hair growth is noted on the frontal scalp. (c)
The frontal scalp and temporal scalp hairs are becoming dense.
Table 1: Patient demographics.
Initials Study group Age Atopic Concomitant disorders Smoker Hamilton Norwood Scale
KC D 33 No NONE NO IV
JW D 38 No NONE NO IV/V
RR A 24 Yes SD NO VII
AR A 38 Yes AD, SD NO II
SS D 50 No NONE NO III
HC C 38 Yes SD, AD∗∗ NO V
CK A 43 Yes SD NO VII
RK D 72 No MS∗ NO III
NC A 42 Yes SD, AD∗∗ NO VII
JG A 32 Yes SD NO VII
AR B 38 No NONE YES III
AH D 45 Yes SD NO VII
RA A 30 Yes SD YES V
WM A 59 Yes SD NO II
JH A 36 Yes SD NO IV




∗∗Severe atopic dermatitis.ISRN Dermatology 5
Day no. 30-patient (no. 6) group C
(a)
  Day no. 90-patient (no. 6) group C
(b)
Day no. 180-patient (no. 6) group C
(c)
Figure 7: (a) Scalp vertex at day no. 30 already shows growth. (b) Scalp vertex at day no. 90. (c) Scalp vertex at day no. 180 (6 months)
demonstrates major growth.
Day no. 1-patient (no. 6) group C
(a)
Day no. 90-patient (no. 6) group C
(b)
Day no. 90-patient (no. 6) group C
(c)
Figure 8: (a) Anterior scalp demonstrates major thinning and poorly deﬁned hairline. (b) Frontal scalp and hairline are growing in at day
no. 90. (c) Frontal scalp and hairline are much thicker at day no. 90.
Another important medication which inhibits 5AR is
dutasteride, (Avodart-GSK). There has been signiﬁcant
attention towards dutasteride as it is the only known
medication which blocks both types of 5-alpha reductase
(types I and II). Type I 5AR is the principle isoenzyme
found in sebaceous and sweat glands and the scalp [5, 14–
19], whereas type II 5AR is present in hair follicles and the
prostate [14]. In addition to blocking both isoenzymes of
5AR (I and II), dutasteride has been shown to be 3 times
more potent then ﬁnasteride at inhibiting type II 5AR and
more than 100 times potent at inhibiting type I isoenzyme.
Oral dutasteride also decreases serum DHT by upto 90%,
whereas ﬁnasteride only reduces concentrations of serum
DHT by 70% [5, 20]. These properties make dutasteride a
more ideal candidate for treating MPB. Despite these more
desirable properties, limited research using dutasteride for
MPB treatment has been undertaken.
Initially, phase I and II clinical trials for dutasteride
as a hair loss drug were undertaken, but called oﬀ in
late 2002. The reason these trials were called oﬀ is not
publicly known. Industry sources speculate that dutasteride
would have been seen as too similar to Propecia (1mg/day
ﬁnasteride) if have been proven proﬁtable on the market as
a hair loss treatment [5] .H o w e v e r ,p h a s eI Is t u d yr e s u l t s
indicated that oral dutasteride at both 0.5mg and 2.5mg/day
generated a superior hair count to ﬁnasteride 5mg at 12
and 24 weeks (Olsen et al.) [5]. In this study, 3 diﬀerent
doses of dutasteride were equal to or more eﬀective than
ﬁnasteride at increasing hair counts. The most eﬀective
dose was found to be 2.5mg of dutasteride daily, however,
more side eﬀects were seen in this group. Quantitative
hair counts were measured at 24 weeks into the study in
all patients. Hair counts in the placebo group was −32.3
hairs, in the ﬁnasteride 5mg/day group was +75.6 hairs,
in the dutasteride 0.1mg/day group was +78.5 hairs, in the
dutasteride 0.5mg/day group was +94.6 hairs, and in the
dutasteride 2.5mg/day group was +109.6 hairs [5].
2. Methods
15 male patients from our Allergy and Immunology practice
with AGA were followed over a 9-month period, from April
2010 to December 2010. Patients’ ages ranged from 24 years
to 72 years old (Table 1). This study included 10 atopic
patients and 5 non-atopic patients, and each patient was
assessed for evidence of seborrheic dermatitis. Patients with
varying degrees of hair loss were assessed based upon the
Hamilton Norwood Scale (Figures 1 and 17), and all patients6 ISRN Dermatology
Day no. 1-patient (no. 2) group D
(a)
Day no. 90-patient (no. 2) group D
(b)
Figure 9: (a) Diﬀuse thinning of the vertex of the scalp. (b) At day no. 90, the vertex demonstrates much thicker hair and more uniform
distribution of hair.
Day no. 1-patient (no. 2) group D
(a)
Day no. 90-patient (no. 2) group D
(b)
Day no. 90-patient (no. 2) group D
(c)
Figure 10: (a) Frontal scalp demonstrates thinning all the way back to the vertex. (b) At day no. 90, the frontal and vertex parts of the scalp
are much more thick and uniform. (c) Another view with much less glare demonstrates a thick scalp vertex.
were recommended to implement aggressive treatment for
seborrheic dermatitis.
Our research product (NuH Hair) formulation is cur-
rently a trade secret. The overall contents, composition
percentages, and formulation methods are not able to be
revealed.
All patients were started on NuH Hair applied one time
per day. All patients were given the option to add the three
other components to our hair regrowth protocol which
included the following.
(a) Propecia (Merck) 1mg taken daily. Propecia was
included in our protocol because it is currently the
only oral 5-alpha reductase inhibitor on the market
which is FDA approved.
(b) Rogaine (Johnson & Johnson Healthcare Products —
Division of McNeil) Foam 5% applied at least once
per day.
(c) Nizoral (ketoconazole) 2% shampoo applied 2-3
times per week. This shampoo came with strict
instructions for patients to scrub into the scalp for
100seconds and then let the foam remain on the
scalp for 10minutes prior to washing out, for each
application.
All patients had documentation via photographs taken
of their scalp prior to starting their medication regimen.
Each patient served as their own control. All patients had
additional photographs taken of their scalp at months 1, 3,
6, and 9. All patients were assessed to follow medication
compliance, and each patient was seen on a monthly basis.
3. Results
In this study, all 15 patients demonstrated signiﬁcant hair
regrowth using this research protocol. In addition, all
patients reported subjective improvement of the health of
theirscalp,andthiswasconﬁrmedontheirfollowupphysical
examinations. All patients also noted that their pre-existing
hair grew much quicker than it did prior to starting their
protocol. All patients who demonstrated signs of seborrheic
dermatitis (SD) reported signiﬁcant improvement of their
SD. This was also conﬁrmed at their followup examination.
Eight (8) patients (group A) used all 4 components of the
research protocol, ﬁve (5) patients used only NuH Hair
(groupD),one(1)patient(groupC)usedNuHHairand2%
ketoconazole shampoo, and one (1) patient (group B) used
NuH Hair, 2% ketoconazole shampoo, and 1mg PropeciaISRN Dermatology 7
Table 2: Patient subgroups.















No. of patients 8 1 1 5
Presence of seborrheic
dermatitis 811 0
Average time for hair
growth (days) 30 days 30 days 60 days 90 days
Day no. 1-patient (no. 8) group D
(a)
Day no. 30-patient (no. 8) group D
(b)
Day no. 90-patient (no. 8) group D
(c)
Figure 11: (a) Patient with signiﬁcant thinning of the vertex. (b) At day no. 30, this patient demonstrates signiﬁcant regrowth of scalp hair
in the vertex area. This patient only used NuH Hair. (c) Another view of the scalp vertex at day no. 90.
Day no. 1-patient (no. 8) group D
(a)
Day no. 60-patient (no. 8) group D
(b)
Figure 12: (a) Diﬀuse thinning of the frontal scalp noted at day no. 1. (b) At day no. 60, there is asigniﬁcant thickening of the frontal scalp
hairs.
Day no. 1-patient (no. 8) group D
(a)
Day no. 90-patient (no. 8) group D
(b)
Figure 13: (a) At day no. 1, a thin recessed hairline is noted. (b) At day no. 90, the hairline is much thicker, and a full hairline is developing.8 ISRN Dermatology
Day no. 1-patient (no. 10) group A
(a)
Day no. 14-patient (no. 10) group A
(b)
Day no. 90-patient (no. 10) group A
(c)
Figure 14: (a) Patient no. 10 with a 20-year history of AGA and 10-year history of stage 7 (Hamilton Norwood) AGA. (b) After only 14 days
of the 4-part protocol, signiﬁcant hair regrowth occurred at the right frontal scalp and hairline. (c) Diﬀuse hair growth noted at day no. 90
throughout the frontal scalp and vertex.
Day no. 1-patient (no. 11) group B
(a)
Day no. 90-patient (no. 11) group B
(b)
Figure 15: (a) Patient with diﬀuse irregular thinning of the anterior scalp and hairline. (b) Central frontal scalp hairline starting to ﬁll in at
90 days.
(ﬁnasteride) orally each day (Table 2). In one patient who
used all four components (Group A), signiﬁcant growth was
achieved within 14 days (Figure 14). Three patients noted
major growth at 30 days of treatment. Objective growth was
noted in all eight patients by day no. 60 (Figures 1, 2, 3, 4, 5,
6, 7,a n d8).
In the ﬁve patients who only used NuH Hair, all patients
noted signiﬁcant hair regrowth by 3 months of therapy (see
Figures 9, 10, 11, 12,a n d13).
In this study, 10 patients incorporated 2% ketoconazole
shampoo into their regimen. Eight of these patients had
known seborrheic dermatitis (SD) and demonstrated sig-
niﬁcant improvement of their dermatitis after one month
of therapy with 2% Nizoral shampoo. All of the patients
with subjective complaints of scalp irritation, itching, and
discomfort noted resolution of these symptoms within
one month of 2% ketoconazole therapy. All patients were
instructed to continue on the shampoo at least twice per
week regardless of the resolution of their SD. In addition,
all 10 patients who incorporated 2% ketoconazole shampoo
expressed desire to continue treatment with the shampoo
indeﬁnitely.
One patient stopped our study after 60 days for logistic
reasons. He demonstrated signiﬁcant growth at day no.
55. This patient was only using NuH Hair and no other
components (group D). He did not have any complaints
of side eﬀects with the study medication. His results were
included as he demonstrated signiﬁcant response.
Several patients in group D (NuH Hair alone) admitted
to only using the Product 2–4 times per week. These patients
still demonstrated signiﬁcant growth despite not following
the daily protocol (Figures 7, 8, 9, 10,a n d11).
4. Discussion
In this pilot study of 15 patients, all patients demonstrated
newsigniﬁcantnewhairgrowthafterstartingNuHHair.The
eight patients who implemented all 4 components of our
protocol demonstrated the most signiﬁcant and most rapid
growth.Inaddition, onepatientingroupDnotedsigniﬁcant
regrowth 14 days after initiating therapy, and three of these
patients noted hair growth as early as 30 days into treatment.
This study, to our knowledge, is the ﬁrst to demonstrate
early signiﬁcant hair regrowth in men with AGA. Our four-
part protocol is also unique in that it addresses several
underlying causes of hair loss in men simultaneously. This
novelapproachintreatinghairlossiseﬀectiveandrepresentsISRN Dermatology 9
Day no. 1-patient (no. 11) group B
(a)
Day no. 30-patient (no.11) group B
(b)
Day no. 90-patient (no. 11) group B
(c)
Figure 16: (a) Temporal scalp demonstrates recession. Another view of the anterior scalp and hairline. (b) After 30 days, this patient
demonstrates regrowth at the temporal and anterior scalp. (c) Another view of the right temporal scalp and hairline, this time at day no. 90.
an MPB treatment protocol that recommends use of four
components simultaneously.
Those patients who utilized only NuH Hair also demon-
strated signiﬁcant regrowth of their hair. This was seen as
early as 1 month into treatment in 2 patients, at 2 months in
other 2 patients, and at 3 months in one patient. This patient
group also contained subjects who admitted to only using
the product 2-3 times per week during 3 months of therapy.
This altered regimen was done on their own behalf, and not
recommended by the investigators. It is important to note
that because of dutasteride’s 28-day half-life, less frequent
application of topical dutasteride should be suﬃcient once
steady-state concentration levels of dutasteride are present
within the scalp. Because of the long half-life, this should
theoretically be reached after 3–5 months of applying the
solution on a daily basis. This is a secondary objective of our
study and will be researched further over the following 12
months.
Patients who did not have signs or symptoms of seb-
orrheic dermatitis also reported subjective improvement
with use of 2% ketoconazole shampoo. Given ketoconazole’s
antiandrogen eﬀects, it was expected to be eﬀective in
patients with and without seborrheic dermatitis.
With the use of 5% Rogaine and oral Propecia, a
minimum of 4–6 months is required for signiﬁcant clinical
apparent hair growth. Most patients who use Rogaine and
Propecia primarily experience a slowing of hair loss. Our
patients not only experienced cessation of hair loss, but they
also demonstrated signiﬁcant hair growth beginning in 30
days, and certainly within 90 days.
Interestingly, those patients who were smokers demon-
strated the least signiﬁcant hair regrowth. There was one
patient in group A, and the other was in group B (Table 1;
Figures 15-16). It is known that there is an association
between men who smoke and premature AGA. The mech-
anisms of smoking-induced hair loss are multifactorial and
include the eﬀects of cigarette smoke on the dermal hair
papilla microvasculature [21, 22].
All of the patients in group D (NuH Hair alone) were
admitted to only use the product an average of 2-3 times per
week. Despite this regimen, the patients still demonstrated
signiﬁcant hair regrowth. This was likely due to dutasteride’s
I
III III vertex III A
II A
IV V IV A




28-hour half-life. This presents an interesting ﬁnding and
may lead to further research with less frequent application
of our topical product.
T h e r eh a v eb e e nn os i d ee ﬀects so far with the topical
regimens noted in this study. The side eﬀects of oral Propecia
were a signiﬁcant concern in many of our patients. Systemic
side eﬀects including erectile dysfunction, fatigue, breast
enlargement,and decreasedvolumeof semenwerenot noted
in any of our study patients. All of our patients reported no
systemic or local side eﬀects.
5. Side Effects of Dutasteride
As with ﬁnasteride, similar side eﬀects have been noted with
dutasteride only when taken orally. These side eﬀects include
gynecomastia, decreased libido, ejaculation disorders, and
impotence. These side eﬀects were resolved in men who
discontinued dutasteride and in most men who continued
therapy.
In addition, ﬁnasteride and dutasteride are absorbed
through the skin. Therefore, women who are pregnant
should not handle these capsules, as contact and inadvertent10 ISRN Dermatology
consumption could cause birth defects of the male fetus.
Men should not donate blood while taking dutasteride.
They should also wait 6 months, after treatment ends,
before donating blood. The long period after discontinuing
dutasteride is based upon a 28-day half-life. dutasteride
can be carried in the blood and can cause birth defects if
a pregnant woman receives a transfusion with blood that
contains dutasteride. These are similar precautions for those
patients taking ﬁnasteride. The absorption through the skin
is signiﬁcant, and this is why we chose to formulate a topical
product to be applied to the scalp.
Another concern in patients taking inhibitors of 5AR is
the risk for prostate cancer. Earlier in this decade, the Pros-
trate Cancer Prevention Trial (PCPT) brought up concern
for ﬁnasteride as a risk for higher-grade prostate cancer. In
this study, despite a 25% reduction of prostate cancers in
the treatment arm (those given 5mg ﬁnasteride per day),
signiﬁcantly more high-grade cancers were demonstrated in
this group. Further evaluation of this study demonstrated
that this increased incidence was attributed to optimized
tumor detection in smaller glands. Prostatic intraepithelial
dysplasia(PIN)wasalsoreducedinthesepatients[23,24].In
another study, the REDUCE trial, a randomized controlled
trial of 6,729 men compared dutasteride to placebo for
the prevention of prostate cancer. These researchers found
an overall reduction of 22% in the incidence of prostate
cancer over 4 years. However, the reduction was entirely in
Gleason grades 5 and 6 cancers, which are less lifethreatening
and often not treated. In Gleason grades 7–10, which are
lifethreatening, there was no reduction in cancer [23, 24].
6. Conclusion
Our study was a prospective pilot study in 15 patients. It
presentsanoveltechniqueattreatingMPBwithanaggressive
multifaceted approach. The study is limited in that we
did not conduct a double-blind, placebo-controlled study.
However, our study was conducted as a classic pilot study.
Our goal was to design a preliminary study prior to our main
research, in order to check the feasibility and to improve the
design of our research. This goal was met, and it should serve
as a foundation to further investigate this product in a large
sample, double-blind, placebo-controlled prospective study
for MPB.
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